licensingAstraZeneca returns to CSPC with $1.77bn kidney dealAstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases. more ➔
fundraisingOryzon raises €12m to push AML and CNS pipelineSpanish epigenetics biotech Oryzon Genomics has raised €12m in a capital increase and signed a financing agreement with COFIDES that could add another €25m in future share subscriptions. more ➔
Start-upTelum raises €18M to push phage-derived antimicrobials toward clinicSpanish biotech Telum Therapeutics has raised €18 million in Series A financing to move its lead antimicrobial programme toward clinical development. more ➔
financeAbivax cashes in on investor enthusiasm with €807m raiseAbivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative col … more ➔
licensingAlzeCure licenses Alzheimer’s asset to QuantumCell in $2.2bn dealSwedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, … more ➔
M&AIpsen’s buying streak continues with €700m Memo dealParis-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeli … more ➔
StrategyInflaRx seeks to fill void left by Amgen’s Tavneos in EuropeInflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from … more ➔
clinical dataGenmab shares rise following positive epcoritamab phase 3 dataGenmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement … more ➔
Start-upsmartbax extends pre-series A to €6.3 m for new antibioticMunich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a €4.7m pre-Series A first close announced in October 2025. more ➔
clinical dataAbivax answers safety questions with new dataAbivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing … more ➔
